Trial Profile
A retrospective study to evaluate efficacy of switching from intravitreal ranibizumab to aflibercept treatment in patients with wet age-related macular degeneration.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Dec 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 13 Dec 2015 New trial record